Lokaliseret lipohypertrophia under behandling med vaeksthormon

Translated title of the contribution: Localized lipohypertrophy during growth hormone therapy

Henriette Mersebach, Ulla F Feldt-Rasmussen


Accumulation of subcutaneous fat is described in a 51-year-old woman with panhypopituitarism treated on all insufficient pituitary axes, including growth hormone (GH). Malnutrition and alcoholic liver disease caused reduced synthesis of hepatic insulin-like growth factor I (IGF-I), and the function of IGF-I as biochemical marker of the GH effect was compromised. Peripheral levels of GH and IGF-I in tissues may have reached supra physiological levels and induced localised lipohypertrophy. Adjustment of GH treatment should not rest in all cases on IGF-I alone, but also depend on the clinical effect. Adjustment should follow suspected adverse events, such as lipohypertrophy, which is, however, an unusual complication of GH therapy.

Translated title of the contributionLocalized lipohypertrophy during growth hormone therapy
Original languageDanish
JournalUgeskrift for Laeger
Issue number14
Pages (from-to)1930-2
Number of pages3
Publication statusPublished - 1 Apr 2002


Dive into the research topics of 'Localized lipohypertrophy during growth hormone therapy'. Together they form a unique fingerprint.

Cite this